Impaired nonrestricted cytolytic activity in systemic lupus erythematosus: Involvement of a pathway independent of Fas, tumor necrosis factor, and extracellular ATP that is associated with little detectable perforin

Arthritis and Rheumatism

Volumn 40, Issue 6, 1997, Pages 1130-1137

  Stohl, William ^a,d   Elliott, Julie E ^a   Li, Lily ^a   Podack, Eckhard R ^b   Lynch, David H ^c   Jacob, Chaim O ^a  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c AMGEN INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; MONOCLONAL ANTIBODY; PERFORIN; TUMOR NECROSIS FACTOR;

ARTICLE; CELL KILLING; CELL PROLIFERATION; CYTOLYSIS; CYTOTOXICITY; DAUDI CELL; EFFECTOR CELL; EXTRACELLULAR CALCIUM; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PATHOGENESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADENOSINE TRIPHOSPHATE; ANTIGENS, CD95; BURKITT LYMPHOMA; CALCIUM; CYTOTOXICITY, IMMUNOLOGIC; EXTRACELLULAR SPACE; HUMANS; JURKAT CELLS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOTOXIN-ALPHA; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030941741     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780400618     Document Type: Article

References (53)

1. Horwitz DA, Stohl W: T lymphocytes, cytokines, and immune regulation in systemic lupus erythematosus, In, Dubois' Lupus Erythematosus. Fourth edition. Edited by DJ Wallace, BH Hahn. Philadelphia, Lea and Febiger, 1993
2. Stohl W: Impaired generation of polyclonal T cell-mediated cytolytic activity despite normal polyclonal T cell proliferation in systemic lupus erythematosus. Clin Immunol Immunopathol 63: 163-172, 1992
3. Stohl W: Impaired polyclonal T cell cytolytic activity: a possible risk factor for systemic lupus erythematosus. Arthritis Rheum 38:506-516, 1995
4. Stohl W, Elliott JE, Hamilton AS, Deapen DM, Mack TM, Horwitz DA: Impaired recovery and cytolytic function of CD56+ T and non-T cells in systemic lupus erythematosus following in vitro polyclonal T cell stimulation: studies in unselected patients and monozygotic disease-discordant twins. Arthritis Rheum 39: 1840-1851, 1996
5. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ: The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277, 1982
6. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE: Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 35:630-640, 1992
7. Stohl W, Posnett DN, Chiorazzi N: Induction of T cell-dependent B cell differentiation by anti-CD3 monoclonal antibodies. J Immunol 138:1667-1673, 1987
8. Stohl W, Tovar Z, Talal N: Generation of cytolytic activity with anti-CD3 monoclonal antibodies involves both IL-2-independent and -dependent components. J Immunol 144:3718-3725, 1990
9. Alderson MR, Tough TW, Braddy S, Davis-Smith T, Roux E, Schooley K, Miller RE, Lynch DH: Regulation of apoptosis and T cell activation by Fas-specific mAb. Int Immunol 6:1799-1806, 1994
10. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 169:1747-1756, 1989
11. Stohl W, Kunkel HG: Heterogeneity in expression of the T4 epitope in black individuals. Scand J Immunol 20:273-278, 1984
12. Hameed A, Olsen KJ, Cheng L, Fox WM III, Hruban RH, Podack ER: Immunohistochemical identification of cytotoxic lymphocytes using human perform monoclonal antibody. Am J Pathol 140: 1025-1030, 1992
13. + T lymphocytes. J Immunol 144:574-582, 1990
14. Rukavina D, Rubesa G, Gudelj L, Haller H, Podack ER: Characteristics of perforin expressing lymphocytes within the first trimester decidua of human pregnancy. Am J Reprod Immunol 33:394-404, 1995
15. Jacob CO, Lee SK, Strassmann G: Mutational analysis of TNF-α gene reveals a regulatory role for the 3′-untranslated region in the genetic predisposition to lupus-like autoimmune disease. J Immunol 156:3043-3050, 1996
16. Kägi D, Vignaux F, Ledermann B, Bürki K, Depraetere V, Nagata S, Hengartner H, Golstein P: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science 265:528-530, 1994
17. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370:650-652, 1994
18. Kojima H, Shinohara N, Hanaoka S, Someya-Shirota Y, Takagaki Y, Katayama T, Yagita H, Okumura K, Shinkai Y, Alt FW, Matsuzawa A, Yonehara S, Takayama H: Two distinct pathways of specific killing revealed by perforin mutant cytotoxic T lymphocytes. Immunity 1:357-364, 1994
19. Walsh CM, Matloubian M, Liu C-C, Ueda R, Kurahara CG, Christensen JL, Huang MTF, Young JD-E, Ahmed R, Clark WR: Immune function in mice lacking the perforin gene. Proc Natl Acad Sci U S A 91:10854-10858, 1994
20. Massen D, Tschopp J: Isolation of a lytic, pore-forming protein (perforin) from cytolytic T-lymphocytes. J Biol Chem 260:9069-9072, 1985
21. Young JD-E, Cohn ZA, Podack ER: The ninth component of complement and the pore-forming protein (perforin 1) from cytotoxic T cells: structural, immunological, and functional similarities. Science 233:184-190, 1986
22. Zalman LS, Brothers MA, Chiu FJ, Müller-Eberhard HJ: Mechanism of cytotoxicity of human large granular lymphocytes: relationship of the cytotoxic lymphocyte protein to the ninth component (C9) of human complement. Proc Natl Acad Sci U S A 83:5262-5266, 1986
23. Podack ER, Young JD-E, Cohn ZA: Isolation and biochemical and functional characterization of perforin 1 from cytolytic T-cell granules. Proc Natl Acad Sci USA 82:8629-8633, 1985
24. Hoyer M, Meineke T, Lewis W, Zwilling B, Rinehart J: Characterization and modulation of human lymphokine (interleukin 2) activated killer cell induction. Cancer Res 46:2834-2838, 1986
25. Vignaux F, Vivier E, Malissen B, Depraetere V, Nagata S, Golstein P: TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 181:781-786, 1995
26. + cytotoxic T lymphocyte-mediated lysis. J Immunol 150:4303-4314, 1993
27. Walsh CM, Glass AA, Chiu V, Clark WR: The role of the Fas lytic pathway in a perforin-less CTL hybridoma. J Immunol 153:2506-2514, 1994
28. Zanovello P, Bronte V, Rosato A, Pizzo P, Di Virgilio F: Responses of mouse lymphocytes to extracellular ATP. II. Extracellular ATP causes cell type-dependent lysis and DNA fragmentation. J Immunol 145:1545-1550, 1990
29. Filippini A, Taffs RE, Sitkovsky MV: Extracellular ATP in T-lymphocyte activation: possible role in effector functions. Proc Natl Acad Sci U S A 87:8267-8271, 1990
30. Zheng LM, Zychlinsky A, Liu C-C, Ojcius DM, Young JD-E: Extracellular ATP as a trigger for apoptosis or programmed cell death. J Cell Biol 112:279-288, 1991
31. Blanchard DK, McMillen S, Djeu JY: IFN-γ enhances sensitivity of human macrophages to extracellular ATP-mediated lysis. J Immunol 147:2579-2585, 1991
32. Blanchard DK, Wei S, Duan C, Pericle F, Diaz JI, Djeu JY: Role of extracellular adenosine triphosphate in the cytotoxic T-lymphocyte-mediated lysis of antigen presenting cells. Blood 85:3173-3182, 1995
33. Young JD-E, Hengartner H, Podack ER, Cohn ZA: Purification and characterization of a cytolytic pore-forming protein from granules of cloned lymphocytes with natural killer activity. Cell 44:849-859, 1986
34. Young JD-E, Podack ER, Cohn ZA: Properties of a purified pore-forming protein (perforin 1) isolated from H-2-restricted cytotoxic T cell granules. J Exp Med 164:144-155, 1986
35. Isaaz S, Baetz K, Olsen K, Podack E, Griffiths GM: Serial killing by cytotoxic T lymphocytes: T cell receptor triggers degranulation, re-filling of the lytic granules and secretion of lytic proteins via a non-granule pathway. Eur J Immunol 25:1071-1079, 1995
36. + T cells. J Immunol 148:3354-3360, 1992
37. + T lymphocytes during HIV infection. J Immunol 156:2282-2293, 1996
38. + patients. Am J Pathol 146:1542-1555, 1995
39. Liu C-C, Walsh CM, Eto N, Clark WR, Young JD-E: Morphologic and functional characterization of perforin-dcficient lymphokine-activated killer cells. J Immunol 155:602-608, 1995
40. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317, 1992
41. Adachi M, Watanabe-Fukunaga R, Nagata S: Aberrant transcription caused by the insertion of an early transposable element in an intron of the Fas antigen gene of Ipr mice. Proc Natl Acad Sci U S A 90:1756-1760, 1993
42. Wu J, Zhou T, He J, Mountz JD: Autoimmune disease in mice due to integration of an endogenous retrovirus in an apoptosis gene. J Exp Med 178:461-468, 1993
43. Chu J-L, Drappa J, Parnassa A, Elkon KB: The defect in Fas mRNA expression in MRL/lpr mice is associated with insertion of the retrotransposon, ETn. J Exp Med 178:723-730, 1993
44. Lynch DH, Watson ML, Alderson MR, Baum PR, Miller RE, Tough T, Gibson M, Davis-Smith T, Smith CA, Hunter K, Bhat D, Din W, Goodwin RG, Seidin MF: The mouse Fas-ligand gene is mutated in gld mice and is part of a TNF family gene cluster. Immunity 1:131-136, 1994
45. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 76:969-976, 1994
46. Ramsdell F, Seaman MS, Miller RE, Tough TW, Alderson MR, Lynch DH: Gld/gld mice are unable to express a functional ligand for Fas. Eur J Immunol 24:928-933, 1994
47. Cohen PL, Eisenberg RA: Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269, 1991
48. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villartay JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 268:1347-1349, 1995
49. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lympho-proliferative syndrome. Cell 81:935-946, 1995
50. Drappa J, Vaishnaw AK, Sullivan KE, Chu J-L, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 335:1643-1649, 1996
51. Wu J, Wilson J, He J, Xiang L, Schur PH, Mountz JD: Fas ligand mutation in a patient with systemic lupus erythematosus and lymphoproliferative disease. J Clin Invest 98:1107-1113, 1996
52. Lipman ML, Stevens AC, Strom TB: Heightened intragraft CTL gene expression in acutely rejecting renal allografts. J Immunol 152:5120-5127, 1994
53. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD: Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 263:1759-1762, 1994